- Oops!Something went wrong.Please try again later.
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kezar Life Sciences (NASDAQ:KZR) Inc on Monday, setting a price target of $9, which is approximately 49.75% above the present share price of $6.01.
Selvaraju expects Kezar Life Sciences Inc to post earnings per share (EPS) of -$0.50 for the second quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Kezar Life Sciences, with an average price target of $13.5.
The analysts price targets range from a high of $18 to a low of $9.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $0 and a net profit of -$10 million. The company's market cap is $229.45 million.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is a 5-star analyst with an average return of 22.1% and a 55.8% success rate.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.